THE GLOBAL MARKET FOR FIXED-DOSE COMBINATION DRUGS FOR LEADING DISEASES
Fixed-dose combination drugs have been used for some time in certain therapeutic categories such as antihypertensives, although they were often reserved for second- or third-line therapy. With the revolution in the survival rates of patients suffering from human immunodeficiency virus (HIV) infection that occurred with the implementation of fixed-drug combination products for this indication, this delivery technology received a boost of confidence as well as an influx of creative applications to other diseases. For the past several years, a number of fixed-dose combination drugs have been introduced for a variety of diseases, some for the first time in a particular disease category. This report discusses the impact of fixed-dose combination drug technology on these various therapeutic categories, as well as providing assessments and projections of this technology overall.
“The Global Market for Fixed-Dose Combination Drugs for Leading Diseases” analyzes products and applications of fixed-dose combination drugs utilized in the treatment of cardiovascular diseases (hypercholesterolemia and hypertension), diabetes, infectious diseases (bacterial infections, Helicobacter pylori, acquired immune deficiency syndrome—AIDS, HIV infection and tuberculosis), psychiatric disorders (depression and Alzheimer’s disease) and respiratory diseases (asthma and chronic obstructive pulmonary disease—COPD). Not included in this report are combination products used as oral contraceptives, combinations of a drug (such as a monoclonal antibody) and a radioactive component, or combination vaccine products. Also not included are over-the-counter (OTC) and prescription non-systemic fixed-dose combination products.
The scope of this report is worldwide. The Overview section provides a discussion of the history and advantages of fixed-dose combination drug products. Described are the leading diseases for which fixed-dose combination products are available or are projected to be introduced during the forecast period. This section also discusses the various types of products available or in development within the categories included in this report.
The Products and Applications section provides a synopsis of more than 70 fixed-dose combination drug products, including those currently marketed and those in Phase II or later development. Comparative product and sales analyses are provided for individual products. Tables include current and forecasted sales by individual product, when possible, as well as worldwide market size and growth estimates for fixed-dose combination drug categories as a whole.
The section on Industry Structure provides a discussion of strategies employed by big pharmaceutical companies in this decade for a high number of top-selling drug patent expirations, how this phenomenon relates to the overall pharmaceutical industry and biotechnology companies and, in particular, the role of fixed-dose combination drugs in the increasingly competitive pharmaceutical industry.
The section on Company Profiles emphasizes companies that lead the pharmaceutical and biotechnology industry in the research and development of fixed-dose combination drugs and the innovative products they have launched or have in development.
The information and analysis presented in “The Global Market for Fixed-Dose Combination Drugs for Leading Diseases” are important assets in decision-making for managers involved in business development, marketing, market research, product development, mergers and acquisitions, licensing, business management, investment banking and deal creation, and to consultants to the pharmaceutical and biotechnology industry. The study provides a comprehensive analysis of the current markets for fixed-dose combination products and the market potential of promising drugs under development.
The price of this report is US$1950.
About Lynn Grey
Lynn Gray has an A.B. Degree from the University of California, Riverside. Since 1988, she has worked as a researcher/market analyst/writer, specializing in the areas of pharmaceuticals and biotechnology. She has written more than 70 market research reports for companies including BCC Research/Eli Research, FIND/SVP (now Kalorama), Biomedical Business International (now MRI and Market Intelligence
Research Corporation (now Frost & Sullivan Market Intelligence).
About STIX
STIX offers world-class analysis in advanced technology, global markets and applied materials research. Visit the STIX website and discover how STIX can help your business. The STIX study points out the opportunities and how U.S. business interests can best take advantage of them. It is available online at www.stix-market-research.com/
Contact STIX (www.stix-market-research.com)
Editorial Contacts:
Donald Saxman, 281/682-2912
Anna Crull: 830/895-1926
|